Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...
A new £60,000-a-year Alzheimer's drug, said to be the first treatment to slow progression of the memory-robbing disease, is a rip off that results in 'tiny' benefits at the cost of deadly risks ...
Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...
But some experts have long warned that side effects of the drug — called donanemab — massively outweigh its benefits. Now, a new study from the company that produces the medication itself ...